Aclaris Therapeutics (ACRS) stock
ACRS's Quality Score was unchanged on Mon, Oct 5, at -2.
Follow ACRS's trial news. Pro members can get an alert when Aclaris Therapeutics files news, and see its trials, share raises, and its CEO's filings.
We do the work for you. Every stock is scored and ranked, every 15 seconds while the market is open. Here it's 15 minutes behind. Pro members see it live.
What's next for ACRS, and how long its cash lasts
From Aclaris Therapeutics’s SEC filings and ClinicalTrials.gov: the company’s own words, the registry’s dates, and arithmetic, not a forecast. Companies often miss their own dates.
Next step the company has named
Cash runway
About 11 quarters
Dilution on the horizon
- Shelf registration (S-3ASR, filed Aug 6, 2026)
- At-the-market share sales program (S-3ASR, filed Aug 6, 2026)
Insiders
No open-market buys or sales by its officers or directors in their filings of the last year.
FDA dates in the next 60 days
Decision dates and advisory committee meetings the companies have announced in their own filings, soonest first and small companies first.
- In 24 daysINOInovio Pharmaceuticals
INOINO-3107
- In 35 daysNRXPNRX Pharmaceuticals
NRXPDrug not named
- In 47 daysCAPRCapricor Therapeutics
CAPRDrug not named
Why ACRS is down
Aclaris Therapeutics fell 21.4% over the five sessions to Oct 5.
Biotech stocks fell a median 3.2% and the S&P 500 rose 1.2% in those sessions; Aclaris Therapeutics fell 21.4%.
−2Growth sales down 51% on the year, gross margin down 6.3 points
1 more driver, the timeline, and the peer table, for Pro members
3 more things pulling ACRS's score down, for Pro members
What's next
Expected to report Thu Nov 5, before the open
After its last 4 reports it closed -1.9% on average, higher 2 of 4 times.
What would turn ACRS's score around: 8 things, for Pro members
Here is what Pro members see.
- Prices refresh every 2.5 seconds during market hours.
- Optional alerts by push, email, or the bell.
- Add it to your Home Screen and it opens like an app.
ACRS has 1 of 14 checks firing
One per group is shown here.
Also on the chart
- RSI 1429.5
- MACD (12, 26, 9)Below signal
- 50-day average$5.69
- 200-day average$4.45
- ADX 1434.2
- Support$4.23
- Resistance$4.56
- Volume2.2x
How ACRS ranks in Biotech
ACRS is #185 of 300 by Quality Score. The top three are shown with their scores, and more by name.
ONC8/1420
RGEN8/1420
CORT8/1418
ACADOpen for its score
ACETOpen for its score
ACRVOpen for its score
ADMAOpen for its score
ACRS1/14-2
When does ACRS report earnings, and what happens after?
Expected to report Thu Nov 5, before the open (in 30 days). Not yet confirmed by the company.
| Reported | When | Gap | Reaction | 5 sessions |
|---|---|---|---|---|
| Aug 6, 2026Before open | Before open | -0.3% | -4.3% | -8.2% |
| May 7, 2026Before open | Before open | -2.4% | +1.7% | +6.5% |
| Feb 26, 2026Before open | Before open | -4.2% | -5.4% | -6.3% |
| Nov 6, 2025Before open | Before open | +1.3% | +0.4% | +6.6% |
About Aclaris Therapeutics
Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company. It focuses on developing novel drug candidates for immuno-inflammatory diseases using its proprietary KINect drug discovery platform. The company's pipeline consists of the following key product candidates: Bosakitug (ATI-045), an investigational, novel, humanized anti-TSLP monoclonal antibody being developed for patients with severe asthma, COPD, and chronic rhinosinusitis with nasal polyps; ATI-2138, being developed for the potential treatment of T cell-mediated autoimmune diseases; and ATI-052 and ATI-9494. Additionally, it has an investigational product candidate, Lepzacitinib (ATI-1777), which is being focused upon as a potential treatment for atopic dermatitis and potentially other dermatologic conditions.
Pro members see every line of every stock's score.
- Real-time prices, no delay
- Every line of ACRS's score, with the points and the reason
- All 14 checks on ACRS and on all 3,243 stocks
- Every stock ranked, with the chart
- Every filing, and optional alerts on ACRS
Straight Answers
Are the prices delayed?
Only on the public pages, which run at least 15 minutes behind. Pro members, and anyone on a guest pass, see real-time prices: the scanner refreshes every 15 seconds, and your watchlist every few seconds, pre-market and after hours included.
Where does the data come from?
Daily bars, quotes, reference data, headlines, and short interest come from Massive, formerly Polygon, a licensed market data vendor. The age of the quotes is shown at the top of every page. Insider trades, notable holders and profits come straight from the SEC. That means Form 4 filings, 13F filings and XBRL financial data on EDGAR. Government filings come from the public STOCK Act and Office of Government Ethics disclosures. The market-wide headlines on the market line also come from the public headline feeds CNBC, MarketWatch and Yahoo Finance publish, shown as the headline, the source and a link to the article. Splits, dividends, and the financial statements on each ticker page come from the vendor's reference data. The 8-K filings on EDGAR are read for the items that move a price. Five years of history is loaded for every stock. So the 200-day and 52-week checks rest on real history. Options flow is not part of the product.
Do I need an account?
Not to start. Tap any green button and you're in, free, with no email and no password. To keep going, create a free account with Google, Apple, or your email. There is no password to make up.
Is this investment advice?
No. It is a screening tool that scores stocks on the chart, the company's own results, and the news and filings. It does not know your situation and it is not a recommendation to buy or sell anything. Please do your own research.